Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Int J Cancer
    August 2026
  1. XING M, Zhou C, Tang Y, Xu S, et al
    Cross-Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications.
    Int J Cancer. 2026 Aug 19. doi: 10.1002/ijc.70704.
    >> Share

  2. CHOKUNONGA E, Chirenje ZM, Borok M, Makunike-Mutasa R, et al
    Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990-2019.
    Int J Cancer. 2026;159:844-852.
    >> Share

    April 2026
  3. MONBERG TJ, Lorentzen CL, Westergaard MCW, Iversen TZ, et al
    Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.
    Int J Cancer. 2026 Apr 23. doi: 10.1002/ijc.70510.
    >> Share

  4. GENDRAU-SANCLEMENTE N, Figueras A, Medina-Jover F, Marin-Jimenez JA, et al
    Sphingosine-1-Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis.
    Int J Cancer. 2026 Apr 9. doi: 10.1002/ijc.70467.
    >> Share

    February 2026
  5. SAKAGUCHI-MUKAIDA H, Hiramatsu K, Masuda T, Kakuda M, et al
    Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer.
    Int J Cancer. 2026 Feb 26. doi: 10.1002/ijc.70401.
    >> Share

    January 2026
  6. REDL E, Herzog C, Vavourakis C, Barrett J, et al
    The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer.
    Int J Cancer. 2026 Jan 29. doi: 10.1002/ijc.70354.
    >> Share

  7. JIANG M, Yamaguchi K, Hamada K, Hosoe Y, et al
    HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.
    Int J Cancer. 2026 Jan 27. doi: 10.1002/ijc.70341.
    >> Share

  8. SABBAGHIAN A, Lin H, Lim YP
    WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers.
    Int J Cancer. 2026;158:218-231.
    >> Share

    December 2025
  9. WIDJAJA AO, Micallef P, Lycke M, Osterlund T, et al
    Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.
    Int J Cancer. 2025 Dec 9. doi: 10.1002/ijc.70277.
    >> Share

    November 2025
  10. AZAM Z, Zhang X, Wahab R, Hasan MM, et al
    Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers.
    Int J Cancer. 2025 Nov 29. doi: 10.1002/ijc.70268.
    >> Share

  11. HABIBURRAHMAN M, Masrour N, Patel N, Piskorz AM, et al
    Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.
    Int J Cancer. 2025 Nov 1. doi: 10.1002/ijc.70217.
    >> Share

    October 2025
  12. HERNANDEZ-BERNAL F, Bernal KS, Bequet-Romero M, Martin-Bauta Y, et al
    HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results.
    Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70199.
    >> Share

    September 2025
  13. WANG L, Zang Y, Dejenie R, Bing J, et al
    The role of cytokines in ovarian cancer drug resistance.
    Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70099.
    >> Share

  14. ULLAH A, Chen Y, Shen Y, Shen B, et al
    Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer.
    Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70132.
    >> Share

  15. KASPER E, Boulouard F, Basset N, Golmard L, et al
    Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
    Int J Cancer. 2025;157:897-907.
    >> Share

    August 2025
  16. DAUGS K, Brandes D, Yasin L, Anwar A, et al
    Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
    Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70097.
    >> Share

  17. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    >> Share

  18. KAUPPINEN AK, Olkinuora AP, Mecklin JP, Peltomaki PT, et al
    Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
    Int J Cancer. 2025 Aug 7. doi: 10.1002/ijc.70074.
    >> Share

    May 2025
  19. GAMA Q, Wang L, Wu P, Liu S, et al
    Effects of levonorgestrel-releasing intrauterine system on recurrence and fertility outcomes during assisted reproduction after complete remission of early endometrioid endometrial cancer and precancerous lesions: A retrospective cohort study.
    Int J Cancer. 2025 May 14. doi: 10.1002/ijc.35465.
    >> Share

    April 2025
  20. WITJES VM, de Hullu JA, Hermkens DMA, Smolders YHCM, et al
    Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.
    Int J Cancer. 2025 Apr 16. doi: 10.1002/ijc.35440.
    >> Share

    March 2025
  21. WEI W, Zhang Y, Li Y, Huang J, et al
    Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35387.
    >> Share

    January 2025
  22. LOFLING LL, Stoer NC, Sloan EK, Nafisi S, et al
    Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
    Int J Cancer. 2025 Jan 26. doi: 10.1002/ijc.35348.
    >> Share

  23. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    >> Share

    December 2024
  24. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
    Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
    Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
    >> Share

  25. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
    Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
    Int J Cancer. 2024;155:2201-2210.
    >> Share

    November 2024
  26. JENSEN A, Guleria S, Albieri V, Nohr B, et al
    Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.
    Int J Cancer. 2024 Nov 14. doi: 10.1002/ijc.35251.
    >> Share

    October 2024
  27. BIGNOTTI E, Simeon V, Ardighieri L, Kuhn E, et al
    TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203.
    >> Share

    September 2024
  28. JONSSON S, Jonsson H, Lundin E, Haggstrom C, et al
    Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35180.
    >> Share

  29. NA R, Jordan SJ, DeFazio A, Williams M, et al
    Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.
    Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35154.
    >> Share

    August 2024
  30. VLEDDER A, Paijens ST, Loiero D, Maagdenberg A, et al
    B cells critical for outcome in high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35149.
    >> Share

    July 2024

  31. Expression of Concern: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35121.
    >> Share

  32. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    >> Share

    June 2024

  33. Correction to "Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer".
    Int J Cancer. 2024 Jun 21. doi: 10.1002/ijc.35059.
    >> Share

  34. ALHARBI M, Lai A, Godbole N, Guanzon D, et al
    Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.
    Int J Cancer. 2024 Jun 7. doi: 10.1002/ijc.35055.
    >> Share

    May 2024
  35. CHAO X, Kai Z, Wu H, Wang J, et al
    Fragmentomics features of ovarian cancer.
    Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
    >> Share

  36. HUANG C, Bu H, Wang Y, Chu R, et al
    Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
    Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
    >> Share

  37. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
    Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
    Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
    >> Share

  38. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
    Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
    Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
    >> Share

    April 2024
  39. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
    Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
    Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
    >> Share

    March 2024
  40. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
    Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
    >> Share

  41. HOLY P, Hlavac V, Seborova K, Susova S, et al
    Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
    >> Share

    February 2024
  42. GIZAW M, Parkin DM, Stoter O, Bukirwa P, et al
    Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study.
    Int J Cancer. 2024 Feb 10. doi: 10.1002/ijc.34877.
    >> Share

    January 2024
  43. WANG X, Sun J, Liu Y, Lin Z, et al
    Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34844.
    >> Share

    October 2023
  44. XIA D, Xu X, Du P
    Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34785.
    >> Share

  45. KIM YN, Joung JG, Park E, Kim JW, et al
    Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34786.
    >> Share

  46. HERZOG C, Jones A, Evans I, Reisel D, et al
    Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
    Int J Cancer. 2023 Oct 20. doi: 10.1002/ijc.34757.
    >> Share

    August 2023
  47. KIM YN, Joung JG, Park E, Kim JW, et al
    Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34696.
    >> Share

    June 2023
  48. FRANDSEN CLB, Svendsen PF, Nohr B, Viuff JH, et al
    Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study.
    Int J Cancer. 2023 Jun 26. doi: 10.1002/ijc.34574.
    >> Share

    May 2023
  49. FORTNER RT, Trewin-Nybraten CB, Paulsen T, Langseth H, et al
    Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
    Int J Cancer. 2023 May 25. doi: 10.1002/ijc.34576.
    >> Share

    March 2023
  50. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    >> Share

  51. SILVA R, Glennon K, Metoudi M, Moran B, et al
    Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
    >> Share

    February 2023
  52. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    >> Share

    January 2023
  53. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
    Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
    Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
    >> Share

    December 2022
  54. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
    A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
    Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016